Antibiotic management of ventilator-associated pneumonia due to antibiotic-resistant gram-positive bacterial infection

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 24, Issue 12, 2005, Pages 794-803

  Kollef, M H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; CORTICOSTEROID; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; GLYCOPEPTIDE; LEVOFLOXACIN; LINEZOLID; PENICILLIN G; RIFAMPICIN; TEICOPLANIN; TELITHROMYCIN; TETRACYCLINE; TOBRAMYCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIAL VIRULENCE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DISEASE ASSOCIATION; DISEASE SEVERITY; GRAM POSITIVE BACTERIUM; HEART DISEASE; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PATHOGENESIS; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; SHORT COURSE THERAPY; STREPTOCOCCUS PNEUMONIAE; TREATMENT FAILURE; TREATMENT OUTCOME; VENTILATOR ASSOCIATED PNEUMONIA;

CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; EQUIPMENT CONTAMINATION; HUMANS; PNEUMONIA, PNEUMOCOCCAL; PNEUMONIA, STAPHYLOCOCCAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TREATMENT FAILURE; VANCOMYCIN; VENTILATORS, MECHANICAL; VIRULENCE;

EID: 29944445890     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-005-0053-3     Document Type: Review

References (67)

1. Lynch JP (2001) Hospital-acquired pneumonia: risk factors, microbiology, and treatment. Chest 119(Suppl 2):373S-384S
2. Diekema DJ, Pfaller MA, Schmitz FJ et al (2001) Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 32(Suppl 2):S114-S132
3. Centers for Disease Control and Prevention (2003) National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992 through June 2003, issued August 2003. http://www.cdc.gov/ncidod/hip/NNIS/ 2003NNISReport _AJIC.PDF. Cited 14 March 2005
4. Centers for Disease Control and Prevention (1999) Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus - Minnesota and North Dakota, 1997-1999. JAMA 282:1123-1125
5. Francis JS, Doherty MC, Lopatin U et al (2005) Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 40:100-107
6. Gillet Y, Issartel B, Vanhems P et al (2002) Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 359:753-759
7. Bartlett JG, Mundy LM (1995) Community-acquired pneumonia. N Engl J Med 333:1618-1624
8. Doern GV, Brueggemann A, Holley HP, et al (1996) Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother 40:1208-1213
9. Thornsberry C, Jones ME, Hickey ML et al (1999) Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998. J Antimicrob Chemother 44:749-759
10. Beekmann SE, Heilmann KP, Richter SS et al (2005) Antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and group A â-haemolytic streptococci in 2002-2003: results of the multinational GRASP Surveillance Program. Int J Antimicrob Agents 25:148-156
11. Chastre J, Fagon JY (2002) Ventilator-associated pneumonia. Am J Respir Crit Care Med 165:867-903
12. Kollef MH (1999) The prevention of ventilator-associated pneumonia. N Engl J Med 340:627-634
13. Centers for Disease Control and Prevention (1996) National Nosocomial Infections Surveillance (NNIS) report, data summary from October 1986-April 1996, issued May 1996. Am J Infect Control 24:380-388
14. Trouillet JL, Chastre J, Vuagnat A et al (1998) Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 157:531-539
15. Rello J, Torres A, Ricart M et al (1994) Ventilator-associated pneumonia by Staphylococcus aureus: comparison of methicillin-resistant and methicillin-sensitive episodes. Am J Respir Crit Care Med 150 (6 Pt 1):1545-1549
16. Centers for Disease Control and Prevention (2003) Methicillin-resistant Staphylococcus aureus infections among competitive sports participants - Colorado, Indiana, Pennsylvania, and Los Angeles County, 2000-2003. MMWR Morb Mortal Wkly Rep 52:793-795
17. Centers for Disease Control and Prevention (2003) Methicillin-resistant Staphylococcus aureus infections in correctional facilities - Georgia, California, and Texas, 2001-2003. MMWR Morb Mortal Wkly Rep 52:992-996
18. Centers for Disease Control and Prevention (2004) Community-associated methicillin-resistant Staphylococcus aureus infections in Pacific islanders - Hawaii, 2001-2003. MMWR Morb Mortal Wkly Rep 53:767-770
19. Naimi TS, LeDell KH, Como-Sabetti K, (2003) Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 290:2976-2984
20. Kazakova SV, Hageman JC, Matava M et al (2005) A clone of methicillin-resistant Staphylococcus aureus among professional football players. N Engl J Med 352:468-475
21. Whitby M, McLaws ML, Berry G (2001) Risk of death from methicillin-resistant Staphylococcus aureus bacteraemia: a meta-analysis. Med J Aust 175:264-267
22. Foster TJ (2004) The Staphylococcus aureus "superbug". J Clin Invest 114:1693-1696
23. Lina G, Piemont Y, Godail-Gamot F et al (1999) Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 29:1128-1132
24. Chen DK, McGeer A, de Azavedo JC et al (1999) Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 341:233-239
25. Centers for Disease Control and Prevention (2001) Resistance of Streptococcus pneumoniae to fluoroquinolones - United States, 1995-1999. MMWR Morb Mortal Wkly Rep 50:800-804
26. Doern GV, Brueggemann AB, Huynh H et al (1999) Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997-98. Emerg Infect Dis 5:757-765
27. American Thoracic Society (1996) Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies: a consensus statement. Am J Respir Crit Care Med 53:1711-1725
28. American Thoracic Society, Infectious Diseases Society of America (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171:388-416
29. Hiramatsu K, Hanaki H, Ino T et al (1997) Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 40:135-136
30. Centers for Disease Control and Prevention (1997) Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. MMWR Morb Mortal Wkly Rep 46:765-766
31. Ploy MC, Grelaud C, Martin C et al (1998) First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 351:1212
32. Kim M-N, Pai CH, Woo JH et al (2000) Vancomycin-intermediate Staphylococcus aureus in Korea. J Clin Microbiol 38:3879-3881
33. Oliveira GA, Dell'Aquila AM, Masiero RL et al (2001) Isolation in Brazil of nosocomial Staphylococcus aureus with reduced susceptibility to vancomycin. Infect Control Hosp Epidemiol 22:443-448
34. Krzyszton-Russjan J, Gniadkowski M, Polowniak-Pracka H et al (2002) The first Staphylococcus aureus isolates with reduced susceptibility to vancomycin in Poland. J Antimicrob Chemother 50:1065-1069
35. Ferraz V, Duse AG, Kassel M et al (2000) Vancomycin-resistant Staphylococcus aureus occurs in South Africa. S Afr Med 190:1113
36. Centers for Disease Control and Prevention (2002) Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR Morb Mortal Wkly Rep 51:565-567
37. Howden BP, Ward PB, Charles PGP et al (2004) Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 38:521-528
38. Fridkin SK, Hageman J, McDougal LK et al (2003) Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis 36:429-439
39. National Committee for Clinical and Laboratory Standards (2003) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A6. NCCLS, Villanova, PA, USA
40. Brown DFJ (2001) Detection of methicillin/oxacillin resistance in staphylococci. In: Susceptibility testing guide. British Society for Antimicrobial Chemotherapy. http://bsac.test.tmg.co.uk/susceptibility_testing/ guide_to_antimicrobial_susceptibility_testing. cfm. Cited 15 June 2005
41. Centers for Disease Control and Prevention (2000) Staphylococcus aureus with reduced susceptibility to vancomycin - Illinois, 1999. MMWR Morb Mortal Wkly Rep 48:1165-1167
42. Moise PA, Forrest A, Bhavnani SM et al (2000) Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am J Health System Pharm 57(Suppl 2): S4-S9
43. Shelburne SA, Musher DM, Hulten K et al (2004) In vitro killing of community-associated methicillin-resistant Staphylococcus aureus with drug combinations. Antimicrob Agents Chemother 48:4016-4019
44. Gonzalez C, Rubio M, Romero-Vivas J et al (1999) Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 29:1171-1177
45. Levine DP, Fromm BS, Reddy BR (1991) Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 115:674-680
46. Wunderink RG, Rello J, Cammarata SK et al (2003) Linezolid vs. vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124:1789-1797
47. Lamer C, de Beco V, Soler P et al (1993) Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 37:281-286
48. Charles PG, Ward PB, Johnson PDR et al (2004) Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 38:448-451
49. Sakoulas G, Moise-Broder PA, Schentag J et al (2004) Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 42:2398-2402
50. Albrecht LM, Rybak MJ, Warbasse LH et al (1991) Vancomycin protein binding in patients with infections caused by Staphylococcus aureus. DICP 25:713-715
51. Morita K, Yamaji A (1995) Changes in the serum protein binding of vancomycin in patients with methicillin-resistant Staphylococcus aureus infection: the role of serum alpha 1-acid glycoprotein levels. Ther Drug Monit 17:107-112
52. Fagon J, Patrick H, Haas DW, Nosocomial Pneumonia Group (2000) Treatment of gram-positive nosocomial pneumonia: prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Am J Respir Crit Care Med 161(3 Pt 1): 753-762
53. Kollef MH, Rello J, Cammarata SK et al (2004) Clinical cure and survival in gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 30:388-394
54. Wilcox M, Nathwani D, Dryden M (2004) Linezolid compared with teicoplanin for the treatment of suspected or proven gram-positive infections. J Antimicrob Chemother 53:335-344
55. Cepeda JA, Whitehouse T, Cooper B et al (2004) Linezolid versus teicoplanin in the treatment of gram-positive infections in the critically ill: a randomized, double-blind, multicentre study. J Antimicrob Chemother 53:345-355
56. Cubicin [prescribing information] (2003) Cubist Pharmaceuticals, Lexington, Mass, USA. http://www.cubicin.com/full prescribing.htm#section06. Cited 10 June 2005
57. Ohlsen K, Ziebuhr W, Koller KP et al (1998) Effects of subinhibitory concentrations of antibiotics on alpha-toxin (hla) gene expression of methicillin-sensitive and methicillin-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother 42:2817-2823
58. van Langevelde P, van Dissel JT, Meurs CJ et al (1997) Combination of flucloxacillin and gentamicin inhibits toxic shock syndrome toxin 1 production by Staphylococcus aureus in both logarithmic and stationary phases of growth. Antimicrob Agents Chemother 41:1682-1685
59. Siberry GK, Tekle T, Carroll K et al (2003) Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 37:1257-1260
60. National Committee for Clinical Laboratory Standards (1997) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A4. NCCLS, Wayne, PA, USA
61. National Committee for Clinical and Laboratory Standards (2004) Performance standards for antimicrobial susceptibility testing. 14th informational supplement. Document M100-S14. NCCLS, Wayne, PA, USA
62. Steward CD, Raney PM, Morrell AK et al (2005) Testing for induction of clindamycin resistance in erythromycin-resistant isolates of Staphylococcus aureus. J Clin Microbiol 43:1716-1721
63. Bernardo K, Pakulat N, Fleer S et al (2004) Subinhibitory concentrations of linezolid reduce Staphylococcus aureus virulence factor expression. Antimicrob Agents Chemother 48:544-546
64. Dennesen PJ, van der Ven AJ, Kessels AG et al (2001) Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Respir Crit Care Med 163:1371-1375
65. Micek ST, Ward S, Fraser VJ, Kollef MH (2004) A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 125:1791-1799
66. Chastre J, Wolff M, Fagon JY et al (2003) Comparison of 8 vs. 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 290:2588-2598
67. Ibrahim EH, Ward S, Sherman G et al (2001) Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 29:1109-1115